Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 10
Submit an article Journal homepage
344
Views
12
CrossRef citations to date
0
Altmetric
Letters to the Editor

Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma

Binod DhakalDepartment of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; View further author information
,
Adam PagenkopfDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
,
Muhammad Umair MushtaqDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
,
Ashley M. CunninghamDivision of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; View further author information
,
Evan FlietnerDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
,
Zachary MorrowDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
,
Athanasios PapadasDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
,
Chelsea HopeDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
,
Catherine LeithDivision of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USAView further author information
,
Peiman HemattiDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
,
Parameswaran HariDepartment of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; View further author information
,
Natalie S. CallanderDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; View further author information
&
Fotis AsimakopoulosDepartment of Medicine, Division of Hematology-Oncology, University of Wisconsin-Madison, Madison, WI, USA; ;University of Wisconsin Carbone Cancer Center, Madison, WI, USA; Correspondence[email protected]
View further author information
 show all
Pages 2558-2562 | Received 16 Nov 2018, Accepted 11 Feb 2019, Published online: 08 Mar 2019

References

  • Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4:343–350.
  • Guillerey C, Harjunpaa H, Carrie N, et al. TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood. 2018;132:1689–1694.
  • Minnie SA, Kuns RD, Gartlan KH, et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood. 2018;132:1675–1688.
  • Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4:61–71.
  • Suen H, Brown R, Yang S, et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia. 2016;30:1716–1724.
  • Plaumann J, Engelhardt M, Awwad MHS, et al. IL-10 inducible CD8(+) regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells. Cancer Immunol Immunother. 2018;67:1695–1707.
  • Muthu Raja KR, Kubiczkova L, Rihova L, et al. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One. 2012;7:e49446.
  • Tang M, Diao J, Gu H, et al. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 2015;13:2851–2864.
  • Hope C, Foulcer S, Jagodinsky J, et al. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016;128:680–685.
  • Arana P, Zabaleta A, Lasa M, et al. High-throughput characterization and new insight into the role of tumor associated macrophages (TAMs) in multiple myeloma (MM). Blood. 2016;128:482–482.
  • Hope C, Emmerich PB, Papadas A, et al. Versican-derived matrikines regulate Batf3-dendritic cell differentiation and promote T cell infiltration in colorectal cancer. J Immunol. 2017;199:1933–1941.
  • Spranger S, Dai D, Horton B, et al. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711–723.e714.
  • Nandadasa S, Foulcer S, Apte SS. The multiple, complex roles of versican and its proteolytic turnover by ADAMTS proteases during embryogenesis. Matrix Biol. 2014;35:34–41.
  • Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013;19:3640–3648.
  • Jensen JL, Rakhmilevich A, Heninger E, et al. Tumoricidal effects of macrophage-activating immunotherapy in a murine model of relapsed/refractory multiple myeloma. Cancer Immunol Res. 2015;3:881–890.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.